We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Greenlights First CAR-T Therapy for Multiple Myeloma Patients
FDA Greenlights First CAR-T Therapy for Multiple Myeloma Patients
The FDA has granted approval for Bristol Myers Squibb’s and bluebird bio’s personalized immune-cell therapy Abecma (idecabtagene vicleucel; ide-cel) for multiple myeloma in adults, marking the first chimeric antigen receptor (CAR) T-cell therapy for the plasma-cell cancer.